Bone Biologics announced the pricing of its public offering. Total gross proceeds are expected to be approximately $2.0 million. Net proceeds will fund clinical trials, maintain and extend its patent portfolio, and support working capital and other general corporate purposes.
NELL-1 is a recombinant human protein that Bone Biologics licensed through a technology transfer agreement with the UCLA Technology Development Group for worldwide applications. NELL-1 combined with demineralized bone matrix forms the product candidate NB1.
In 2023, the company received approval to commence a multicenter pilot clinical trial to evaluate the NB1 bone graft in Australia. This pilot study will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion to treat degenerative disc disease.
Bone Biologics is undertaking work with select strategic partners that builds on the preclinical research of the Nell-1 protein. The company is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.
Bone Biologics announced the pricing of its public offering. Total gross proceeds are expected to be approximately $2.0 million. Net proceeds will fund clinical trials, maintain and extend its patent portfolio, and support working capital and other general corporate purposes.
NELL-1 is a recombinant human protein that Bone Biologics licensed...
Bone Biologics announced the pricing of its public offering. Total gross proceeds are expected to be approximately $2.0 million. Net proceeds will fund clinical trials, maintain and extend its patent portfolio, and support working capital and other general corporate purposes.
NELL-1 is a recombinant human protein that Bone Biologics licensed through a technology transfer agreement with the UCLA Technology Development Group for worldwide applications. NELL-1 combined with demineralized bone matrix forms the product candidate NB1.
In 2023, the company received approval to commence a multicenter pilot clinical trial to evaluate the NB1 bone graft in Australia. This pilot study will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion to treat degenerative disc disease.
Bone Biologics is undertaking work with select strategic partners that builds on the preclinical research of the Nell-1 protein. The company is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.
Copy to clipboard 
